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n May 2009, the National Institute for Health and Clinical Excellence published new guidance on the management of type 2 diabetes. 1 The guidance offered a blueprint for when, and to which patients, newer antidiabetic medicines (eg, incretin mimetics, thiazolidinediones) should be offered. The Scottish Intercollegiate Guideline Network published guidelines 2 on the management of diabetes in 2001 but these do not offer detailed recommendations for type 2 diabetes treatment or on glycaemic control and are not recent enough to include some of the newer medicines.
This article summarises the available pharmacological treatments for people with type 2 diabetes, in the context of the recent NICE recommendations (although insulin treatment is not discussed in great detail).
Lifestyle advice
After being diagnosed with type 2 diabetes, patients should first be offered lifestyle advice -such as information on healthy eating and physical activity. This should incorporate recommendations to:
• Include high-fibre, low-glycaemic-index sources of carbohydrate (eg, beans, wholegrain breads) • Include low-fat dairy products and oily fish • Limit intake of foods containing saturated fats and trans fatty acids (eg, butter, cheese)
The aims are to help the patient achieve and maintain a HbA 1c target of <6.5% (<48mmol/mol; see Box 1, p480) and, if he or she is overweight, lose 5-10% of body weight. Each patient should be offered therapy (lifestyle and medicines) to help achieve and maintain the HbA 1c target level.
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Metformin
Metformin is generally considered the gold standard treatment for type 2 diabetes. It has several pharmacological actions, which include:
• Reducing hepatic glucose production • Inhibiting intestinal absorption of glucose • Increasing glucose utilisation by enhancing the action of insulin at peripheral receptors • Increasing glucose uptake by muscles Because metformin has no effect on insulin release it is unlikely to cause hypoglycaemia. The starting dose of metformin is usually 500mg daily, which is increased to a usual maximum of 1g twice a day (or 850mg three times a day). The dose is often limited by gastrointestinal side effects, such as diarrhoea, although these are often overcome by titrating the dose up slowly or switching to a modified-release formulation.
Advantages of metformin over other oral antidiabetic medicines include: it does not cause weight gain; and there is strong evidence to confirm that it reduces the risk of myocardial infarction and death among diabetic patients. If the HbA1c remains above 7.5% (59mmol/mol) despite treatment with metformin and a sulphonylurea, the patient should be offered insulin. Third-line alternatives include thiazolidinediones and the newer dipeptidylpeptidase-4 inhibitors and incretin mimetics (restricted to certain patient groups).
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Renal failure Metformin is excreted renally; therefore, pharmacists should review the kidney function of all patients for whom it is prescribed. Metformin should be stopped if a patient's estimated glomerular filtration rate falls below 30ml/min/1.73m 2 or if the patient experiences a sudden deterioration in kidney function.
Sulphonylureas
Sulphonylureas augment the body's residual insulin function by enhancing the release of insulin from pancreatic islet beta cells and increasing tissue sensitivity to insulin. Sulphonylureas might also increase the number of insulin receptors on cells. It is common for sulphonylureas to cause hypoglycaemia.
When choosing a sulphonylurea the duration of action should be taken into account. A short-acting sulphonylurea (eg, gliclazide) is an appropriate choice, particularly if the patient is elderly or has compromised kidney function, since both of these groups are at increased risk of developing hypoglycaemia.. All patients who start sulphonylurea treatment should be counselled on the risk of hypoglycaemia and its management (see Box 2). They need to be able to recognise a "hypo" and treat it quickly and effectively.
Sulphonylureas can cause weight gain. This is a particular issue for patients with type 2 diabetes, most of whom are already overweight.
According to NICE, sulphonylureas can be considered first-line for patients who are not overweight. Otherwise, they can be added to metformin if a patient's HbA 1c fails to drop below 6.5% (48mmol/mol) after proactive dose titration of metformin monotherapy. NICE recommends selecting a sulphonylurea with a low cost, although the use of glibenclamide is not recommended because of its long duration of action and hence increased risk of hypoglycaemia.
Meglitinides
Also known as insulin secretagogues or postprandial regulators, meglitinides (eg, repaglinide, nateglinide) have a pharmacologically distinct mechanism of action from that of the sulphonylureas.
They stimulate insulin release by, in the presence of glucose, closing the K + -ATP channels found on the surface of pancreatic beta cells. This enables a postprandial glycaemic response so, to work effectively, the medicines must be taken less than 30 minutes before eating a meal. They are particularly useful for people with erratic lifestyles who do not eat regularly because they allow patients to omit a dose if they miss a meal.
NICE recommends that meglitinides are used in place of sulphonylureas for such patients.
Acarbose
Alpha glucosidase inhibitor acarbose works by preventing the breakdown of carbohydrate in the gastrointestinal tract. This delays the digestion and absorption of glucose and therefore reduces postprandial blood glucose levels.
Acarbose is rarely used because of its limited effect on reducing HbA 1c and its unpleasant gastrointestinal side effects (eg, diarrhoea, abdominal pain, bloating). NICE
Box 2: Managing hypoglycaemia
It is important for pharmacists to be able to counsel patients on the appropriate management of hypoglycaemia (known as a "hypo"). Symptoms of a hypo include:
The following basic advice can be offered for managing mild hypos:
• Take sugar orally (eg, two teaspoons of sugar in water, 100ml Lucozade, fizzy drink (non-diet), three or four glucose tablets, Glucogel)
• Follow this with a snack or meal (eg, sandwich, glass of milk and biscuit, fruit) Those prescribed acarbose must be made aware that the drug interferes with the absorption of sucrose (and other polysaccharide sugars). Therefore, patients at risk of hypoglycaemia (eg, those also prescribed sulphonylureas or insulin) should use glucose, not sucrose, to treat a hypo.
Insulin
In patients whose HbA 1c remains above 7.5% (59mmol/mol) despite being treated with metformin and a sulphonylurea, NICE recommends adding insulin.
The institute advises starting treatment with a human isophane (NPH) insulin, administered at bedtime or twice daily. Alternatively, a once-daily long-acting insulin analogue (eg, insulin detemir or glargine) can be considered for patients:
• Who require assistance with injecting insulin • Whose lifestyle is significantly restricted by recurrent symptomatic hypoglycaemia • Who would otherwise need twice-daily basal insulin injections in combination with oral antidiabetic medicines • Who cannot use the device needed to inject isophane insulin
In practice, if the decision to start insulin is made it is usual to start once-daily insulin injections and continue metformin at the same dose while reducing the dose of sulphonylurea. Intensifying insulin regimens is beyond the scope of this article.
If insulin use is not appropriate (eg, because of the patient's employment, social, recreational or other personal circumstances, or because he or she is obese), other treatments (below) can be considered for use instead.
Thiazolidinediones
The thiazolidinediones rosiglitazone and pioglitazone are agonists of a nuclear receptor called PPAR-gamma (peroxisomal proliferator activated receptor gamma). They enhance the action of insulin on liver, fat and skeletal muscle cells by:
• Increasing glucose uptake into muscle cells • Reducing insulin resistance • Decreasing hepatic glucose production It should be noted that thiazolidinediones have no effect on insulin secretion and if used as monotherapy could be less likely to cause hypoglycaemia.
Safety concerns
There is consistent evidence that rosiglitazone and pioglitazone can cause weight gain and fluid retention, which can lead to new or worsening heart failure that can be fatal. There is also evidence that rosiglitazone might increase the risk of cardiac ischaemia, particularly when used with insulin, and that pioglitazone and rosiglitazone might increase patients' risk of fracture. 4 According to the Medicines and Healthcare products Regulatory Agency, 5, 6 neither pioglitazone nor rosiglitazone should be prescribed for patients with a history of heart failure or who are at increased risk of fractures. In addition, rosiglitazone should be used with caution for patients with previous or current ischaemic heart disease.
Place in therapy According to NICE, these medicines should be used third-line, behind lifestyle modifications and metformin/sulphonylurea monotherapy. Therefore, if glycaemic control is inadequate, thiazolidinediones could be added to:
• Metformin (if treatment with a sulphonylurea is unsuitable) • A sulphonylurea (if treatment with metformin is unsuitable) • Metformin and a sulphonylurea (if insulin is unsuitable)
Treatment should only be continued if HbA 1c reduces by more than 0.5 percentage points over six months of treatment. The benefits and risks of thiazolidinediones should be discussed with patients before these medicines are prescribed.
Newer treatments
Incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are proteins secreted by intestinal endocrine cells in response to intake of nutrients. They influence glucose homeostasis by:
• Stimulating glucose-dependent insulin secretion • Suppressing glucagon secretion • Slowing gastric emptying • Increasing tissue sensitivity to insulin It was noted in 1986 that people with type 2 diabetes have diminished secretion of GLP-1. 7 
If used
Box 3: Self-monitoring of blood glucose
According to the National Institute for Health and Clinical Excellence, blood glucose self-monitoring should be available for patients:
• Who are using insulin • Who are taking oral glucose-lowering medicines (to help avoid hypoglycaemia)
• To assess changes in glucose control resulting from treatment or lifestyle changes
• To monitor changes during periods of illness • To ensure they can safely carry out activities such as driving However, since self-monitoring of blood glucose represents a significant cost burden to the NHS, the continued need and benefit derived by patients from such monitoring should be reviewed annually. From a practical viewpoint, blood glucose self-monitoring should be restricted to those patients who have a substantial risk of hypoglycaemia and those receiving insulin. (Situations where stable patients are self-testing for testing's sake and the results have no practical purpose should be avoided.) Knowledge of the role of incretins in diabetic patients led to the development of incretin enhancers (ie, DPP-4 inhibitors sitagliptin, vildagliptin, saxagliptin) and incretin mimetics (exenatide, liraglutide). These treatments have been shown to improve glycaemic control in type 2 diabetes.
DPP-4 inhibitors
The first DPP-4 inhibitor to be licensed in the UK was sitagliptin, followed by vildagliptin and, more recently, saxagliptin. DPP-4 inhibitors are generally well tolerated, have a low risk of causing hypoglycaemia and are weight neutral. They are all licensed for use as dual therapy with metformin, a sulphonylurea or a thiazolidinedione. Sitagliptin is also licensed as monotherapy and as triple therapy with metformin and a sulphonyurea/thiazolidinedione.
Place in therapy DPP-4 inhibitors are recommended by NICE as third-line therapy (ie, at the same stage as thiazolidinediones): for patients who do not have adequate glycaemic control after treatment with metformin and/or a sulphonylurea (or for whom these medicines are unsuitable). DPP-4 inhibitors and thiazolidinediones can also be used second-line with a sulphonylurea for patients who cannot take metformin.
NICE suggests that use of a DPP-4 inhibitor might be preferable if the possibility of further weight gain is likely, whereas if a person has marked insulin sensitivity a thiazolidinedione might be preferable.
Since only sitagliptin is licensed for use as triple therapy with metformin and a sulphonylurea, it is the only DPP-4 inhibitor discussed in the recent NICE guideline. Exenatide Exenatide is injected twice daily up to 60 minutes before breakfast and the evening meal. It works by mimicking the action of GLP-1 and is licensed for use with metformin and/or a sulphonylurea. In some specialist diabetes centres, it is also being used out of licence with insulin.
Incretin mimetics
One of the main side effects of exenatide is nausea, which has been reported by 40-50% of patients. Most episodes of nausea are mild to moderate in severity and dose-dependent, and tend to decrease in frequency and severity over time.
A major advantage for exenatide is that it causes weight loss -an effect seen irrespective of the occurrence of nausea. According to the manufacturer, the reduction is larger among those who experience nausea than among those who do not (mean reduction 2.4kg versus 1.7kg from long-term controlled studies up to 52 weeks).
Liraglutide Unlike exenatide, liraglutide is injected subcutaneously once a day. It has a similar licence to exenatide but, in addition, can be used in combination with metformin and a thiazolidinedione.
In an open-label trial published earlier this year, type 2 diabetic patients treated with liraglutide achieved better glycaemic control than those treated with exenatide. Weight loss was similar for the two treatments. 8 Place in therapy According to NICE, exenatide can be added to metformin and a sulphonylurea as a third-line treatment option (ie, as an alternative to insulin, thiazolidinediones or DPP-4 inhibitors) for patients who satisfy the following criteria:
• They have a body mass index ≥35kg/m 2 , are of European descent (adjustments to this BMI threshold should be made for ethnic groups at greater risk of cardiovascular disease) and have medical problems associated with high body weight • They have a BMI <35kg/m 2 but are not able to take insulin (ie, for occupational reasons) or have comorbidities that would benefit from weight loss
The NICE guideline states that exenatide should only be continued in patients who experience at least a 1 percentage point reduction in HbA 1c and who lose at least 3% of their initial body weight after six months. The guideline does not mention liraglutide because the medicine was not available at the time of publication. NICE is expected to publish a single technology appraisal for liraglutide in 2010. In the meantime, the institute's guidance for exenatide is likely to be applied to the use of liraglutide.
